Dyne Therapeutics Submits BLA for Z-Rostudirsen After DELIVER Trial Meets Dystrophin Endpoints

Dyne Therapeutics' biologics license application (BLA) for zeleciment rostudirsen (z-rostudirsen) signals a tightening regulatory timeline for exon-skipping therapies, one that will require manufacturing and QA teams to align CMC documentation, process validation packages, and accelerated approval commitments well ahead of any FDA action. The submission targets patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping and was filed under the accelerated approval pathway.

The BLA is supported by the phase 1/2 DELIVER trial (NCT05524883), which demonstrated statistically significant increases in dystrophin production alongside improvements across multiple functional endpoints and a favorable safety profile. For regulatory affairs leads, the accelerated approval route introduces post-marketing confirmation requirements that must be built into the submission strategy from the outset.

Elsewhere in the advanced therapy pipeline, Liminatus Pharma has entered a definitive merger agreement with InnocsAI LLC, absorbing a CAR-T and antibody-based oncology portfolio targeting hematologic malignancies and solid tumors. InnocsAI's programs are designed to address antigen escape, tumor heterogeneity, and the immunosuppressive tumor microenvironment, technical challenges that carry direct implications for manufacturing process design and comparability strategies as assets transition between entities.

On the manufacturing infrastructure side, Sartorius has opened a €140 million cell and gene therapy competence center in Freiburg, Germany, expanding component manufacturing capacity for the CGT sector. The investment reflects sustained pressure on the supply chain for critical CGT consumables and equipment, a constraint that plant heads scaling autologous or allogeneic platforms have flagged repeatedly across recent production cycles.

Two additional collaborations are reshaping the upstream science. Genethon and Ampersand Biomedicines announced an exclusive research partnership to engineer next-generation adeno-associated virus (AAV) capsids with enhanced tissue specificity, initially targeting skeletal muscle. The collaboration pairs Ampersand's AND platform for cell-specific ligand identification with Genethon's capsid engineering capabilities, with the explicit goal of reducing the high vector doses currently required for nonhepatic targets, a lever with direct consequences for sterility assurance and fill-finish capacity planning. Separately, Kyverna Therapeutics' mivocabtagene autoleucel (miv-cel), an autologous anti-CD19 CAR-T therapy, generated phase 2 data in stiff person syndrome presented at the 2026 American Academy of Neurology Annual Meeting, adding to the evidence base for CAR-T in antibody-mediated autoimmune neurological disease.

Dyne's BLA review timeline will serve as a near-term indicator of FDA's appetite for accelerated approval in the exon-skipping space, with the DELIVER trial's dystrophin production data forming the evidentiary core of that determination.

Source: CGTLive via cgtlive.com, May 27, 2026.